Ribavirin elaidate

Drug Profile

Ribavirin elaidate

Alternative Names: CP-4033; Ribavirin-5'-elaidic acid ester ; UNII-4LU13X0I13

Latest Information Update: 17 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clavis Pharma
  • Developer Translational Therapeutics
  • Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Eukaryotic initiation factor 4E inhibitors; Oncogene protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer

Highest Development Phases

  • No development reported Thyroid cancer

Most Recent Events

  • 17 Nov 2013 No development reported - Preclinical for Thyroid cancer in USA (unspecified route)
  • 09 Oct 2013 Clavis Pharma is now called Aqualis
  • 02 Sep 2011 Ribavirin elaidate receives Orphan Drug status for Thyroid cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top